Restricted accessResearch articleFirst published online 2026-1
Association of IL17A rs4711998 and IL1B rs16944 Polymorphism with Anti-Thyroid Peroxidase Serum Level in Autoimmune Thyroid Diseases: A Case–Control Study in Iranian Population
Autoimmune thyroid diseases (AITDs), including Hashimoto’s thyroiditis and Graves’ disease, are characterized by aberrant immune responses influenced by both genetic predisposition and environmental triggers. Genetic association studies have identified several candidate loci that may contribute to the onset and progression of these conditions. The present study investigates the potential impact of specific genetic polymorphisms in interleukin genes (IL17A, IL1B, IL18) and CTLA-4 on thyroid peroxidase antibody (TPOAb) levels in individuals from northwest Iran.
Results:
A total of 82 individuals with elevated TPOAb levels and 82 antibody-negative controls were genotyped for single nucleotide polymorphisms using the tetra-primer amplification refractory mutation system polymerase chain reaction. The analysis revealed significant associations between specific genetic variants and TPOAb levels. Notably, the AG genotype of IL17A rs4711998 was associated with a protective effect, whereas the AA genotype of IL1B rs16944 was correlated with elevated antibody levels, suggesting a potential role in enhancing autoimmune responses.
Conclusions:
These findings underscore the contribution of genetic variations in interleukin genes to the pathogenesis of AITDs in the northwest Iranian population. Elucidating these associations may enhance our understanding of disease mechanisms and contribute to the development of targeted therapeutic strategies.
BanerjeeS, NaharU, DahiyaD, et al.IL-17 A correlates with disease progression in papillary thyroid carcinoma. Diagn Pathol, 2023; 18(1):93.
2.
BioqueG, CrusiusJB, KoutroubakisI, et al.Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol, 1995; 102(2):379–383.
3.
ChenRH, ChangCT, ChenWC, et al.Proinflammatory cytokine gene polymorphisms among Hashimoto’s thyroiditis patients. J Clin Lab Anal, 2006; 20(6):260–265.
4.
ChenRH, ChenWC, ChangCT, et al.Interleukin-1-beta gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves’ disease. J Clin Lab Anal, 2005; 19(4):133–138.
5.
ChistiakovDA, TurakulovRI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol, 2003; 31(1):21–36.
6.
DongYH, FuDG. Autoimmune thyroid disease: Mechanism, genetics and current knowledge. Eur Rev Med Pharmacol Sci, 2014; 18(23):3611–3618.
7.
DurãesC, MoreiraCS, AlvelosI, et al.Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease. PLoS One, 2014; 9(8):e105492.
8.
FerrariSM, FallahiP, AntonelliA, BenvengaS. Environmental issues in thyroid diseases. Front Endocrinol (Lausanne), 2017; 8:50.
9.
HossenMM, MaY, YinZ, et al.Current understanding of CTLA-4: From mechanism to autoimmune diseases. Front Immunol, 2023; 14:1198365.
10.
HuangfuL, LiR, HuangY, WangS. The IL-17 family in diseases: From bench to bedside. Signal Transduct Target Ther, 2023; 8(1):402.
11.
JagerJ, GrémeauxT, GonzalezT, et al.Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes, 2010; 59(1):61–70.
12.
KhalilzadehO, AnvariM, EsteghamatiA, et al.Graves’ ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Exp Ophthalmol, 2009; 37(6):614–619.
13.
KhalilzadehO, AnvariM, EsteghamatiA, et al.The interleukin-1 family gene polymorphisms and Graves’ disease. Ann Endocrinol (Paris), 2010; 71(4):281–285.
14.
LiuN, LiX, LiuC, et al.The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves’ disease in a case-control study and meta-analysis. Hum Immunol, 2010a;71(4):397–401.
15.
LiuY-H, ChenR-H, WuH-H, et al.Association of interleukin-1beta (IL1B) polymorphisms with Graves’ ophthalmopathy in Taiwan Chinese patients. Invest Ophthalmol Vis Sci, 2010b;51(12):6238–6246.
16.
LiuZ, WangH, XiaoW, et al.Thyrocyte interleukin-18 expression is up-regulated by interferon-γ and may contribute to thyroid destruction in Hashimoto’s thyroiditis. Int J Exp Pathol, 2010c;91(5):420–425.
17.
LuY, XingC, ZhangC, et al.Promotion of IL-17/NF-κB signaling in autoimmune thyroid diseases. Exp Ther Med, 2023; 25(1):51.
18.
MarinouI, WaltersK, DicksonMC, et al.Evidence of epistasis between interleukin 1 and selenoprotein-S with susceptibility to rheumatoid arthritis. Ann Rheum Dis, 2009; 68(9):1494–1497.
19.
MikośH, MikośM, Obara-MoszyńskaM, NiedzielaM. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol, 2014; 65(2):150–155.
20.
MyśliwiecJ, KretowskiA, StepieńA, et al.Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves’ ophthalmopathy treated with corticosteroids. Int Immunopharmacol, 2003; 3(4):549–552.
21.
O’SullivanBJ, ThomasHE, PaiS, et al.IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol, 2006; 176(12):7278–7287.
22.
QiY, ZhengH, LiuN, et al.Genetic association between Interleukin-17A gene polymorphisms and the pathogenesis of Graves’ disease in the Han Chinese population. Clin Endocrinol (Oxf), 2016; 84(2):265–270.
23.
ShuklaSK, SinghG, AhmadS, PantP. Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. Microb Pathog, 2018; 116:279–288.
24.
TakiyamaY, MiyokawaN, TokusashiY, et al.Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: Immunohistochemical detection of interleukin-18 in autoimmune thyroid disease. Thyroid, 2002; 12(11):935–943.
25.
TingW-H, ChienM-N, LoF-S, et al.Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) gene polymorphisms with autoimmune thyroid disease in children and adults: Case-control study. PLoS One, 2016; 11(4):e0154394.
26.
TsaiLJ, HsiaoSH, TsaiJJ, et al.Higher genetic susceptibility to inflammation in mild disease activity of systemic lupus erythematosus. Rheumatol Int, 2009; 29(9):1001–1011.
27.
VaidyaB, Kendall-TaylorP, PearceSHS. The genetics of autoimmune thyroid disease. J Clin Endocrinol Metab, 2002; 87(12):5385–5397.
28.
WangX, LiY, ZhaiX, et al.Reference intervals for serum thyroid-stimulating hormone based on a recent nationwide cross-sectional study and meta-analysis. Front Endocrinol (Lausanne), 2021; 12:660277.
29.
WiersingaWM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul), 2016; 31(2):213–222.
30.
XingD, LiuD, LiR, et al.Factors influencing the reference interval of thyroid-stimulating hormone in healthy adults: A systematic review and meta-analysis. Clin Endocrinol (Oxf), 2021; 95(3):378–389.
31.
YanN, YuY-L, YangJ, et al.Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases. Autoimmunity, 2012; 45(7):533–539.
32.
ZaaberI, MestiriS, HammediH, et al.Association of interleukin-1B and interleukin-4 gene variants with autoimmune thyroid diseases in tunisian population. Immunol Invest, 2016; 45(4):284–297.
33.
ZhaoR, ZhouH, SuSB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol, 2013; 17(3):658–669.
